Relapsed or Refractory Multiple Myeloma: Prospective Study with Bortezomib, Non-Pegylated Liposomal Doxorubicin and Dexamethason (PAD Regimen)

被引：0
|
作者：
Falcone, Antonietta Pia [1 ]
Sanpaolo, Grazia [1 ]
Rossi, Giovanni [2 ]
Bodenizza, Carlo [1 ]
Carella, Angelo Michele [3 ]
Dell' Olio, Matte [1 ]
Greco, Michele Mario [4 ]
La Sala, Antonio [1 ]
Mantuano, Saverio [1 ]
Melillo, Lorella [5 ]
Merla, Emanuela [4 ]
Nobile, Michele [1 ]
Scalzulli, Potito R. [6 ]
Capalbo, Silvana [7 ]
Cascavilla, Nicola [2 ]
机构：
[1] IRCCS Casa Sollievo della Sofferenza Hosp, Dept Hematol & Stem Cell Transplantat, San Giovanni Rotondo, Italy
[2] IRCCS, Hematol & Stem Cell Transplantat Unit, San Giovanni Rotondo, Italy
[3] IRCCS Casa Sollievo della Sofferenza Hosp, Hematol & Stem Cell Transplantat Unit, San Giovanni Rotondo, Italy
[4] IRCCS Casa Sollievo Sofferenza, Hematol & Stem Cell Transplantat Unit, San Giovanni Rotondo, Italy
[5] IRCCS, Hematol & Stem Cell Unit, San Giovanni Rotondo, Italy
[6] IRCCS Casa Sollievo Sofferenza, Hematol Unit, San Giovanni Rotondo, Italy
[7] Osped Riuniti Azienda Osped Univ, Foggia, Italy
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.5032.5032
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5032
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma:: Combination therapy improves time to progression
    Orlowski, Robert Z.
    Nagler, Arnon
    Sonneveld, Pieter
    Blade, Joan
    Hajek, Roman
    Spencer, Andrew
    Hajek, Roman
    Spencer, Andrew
    Miguel, Jesus San
    Robak, Tadeusz
    Dmoszynska, Anna
    Horvath, Noemi
    Spicka, Ivan
    Sutherland, Heather J.
    Suvorov, Alexander N.
    Zhuang, Sen H.
    Parekh, Trilok
    Xiu, Liang
    Yuan, Zhilong
    Rackoff, Wayne
    Harousseau, Jean-Luc
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) : 3892 - 3901
  • [32] Phase I/II study of bortezomib in combination with liposomal doxorubicin and melphalan in relapsed or refractory multiple myeloma.
    Chari, A
    Kaplan, L
    Linker, C
    Damon, LE
    Navarro, WH
    Martin, T
    BLOOD, 2005, 106 (11) : 379B - 379B
  • [33] PEGYLATED LIPOSOMAL DOXORUBICIN IN COMBINATION WITH BORTEZOMIB FOR THE TREATMENT OF RELAPSED MULTIPLE MYELOMA-A COST-EFFECTIVENESS STUDY FOR SCOTLAND
    Gibbons, C. J.
    Yong, K.
    Roberts, G.
    VALUE IN HEALTH, 2008, 11 (06) : A467 - A467
  • [34] A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma
    Berenson, James R.
    Hilger, James D.
    Klein, Leonard M.
    Eshaghian, Shahrooz
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert
    BLOOD, 2012, 120 (21)
  • [35] Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM)
    Sonneveld, P.
    Hajek, R.
    Nagler, A.
    Spencer, A.
    Blade, J.
    Robak, T.
    Zhuang, S. H.
    Harousseau, J. L.
    Fruchtman, S.
    Orlowski, R. Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] Effect of disease stage and time since diagnosis on time to progression for pegylated liposomal doxorubicin plus bortezomib vs bortezomib alone in relapsed or refractory multiple myeloma
    Sutherland, Heather J.
    Blade, Joan
    Miguel, Jesus San
    Nagler, Amon
    Sonneveld, Pieter
    Spencer, Andrew
    Robak, Tadeusz
    O'Neal, Wane
    Mundle, Sudeel D.
    Zhuang, Sen H.
    Harousseau, Jean-Luc
    Orlowski, Robert Z.
    BLOOD, 2007, 110 (11) : 805A - 805A
  • [37] Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy
    Baz, R.
    Walker, E.
    Karam, M. A.
    Choueiri, T. K.
    Jawde, R. A.
    Bruening, K.
    Reed, J.
    Faiman, B.
    Ellis, Y.
    Brand, C.
    Srkalovic, G.
    Andresen, S.
    Knight, R.
    Zeldis, J.
    Hussein, M. A.
    ANNALS OF ONCOLOGY, 2006, 17 (12) : 1766 - 1771
  • [38] A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML
    Jonas, Brian A.
    Potter, Laura A.
    Galkin, Maria
    Tuscano, Joseph M.
    LEUKEMIA RESEARCH REPORTS, 2023, 19
  • [39] PHASE I STUDY OF NON-PEGYLATED LIPOSOMAL DOXORUBICIN IN CHILDREN WITH RECURRENT/REFRACTORY HIGH GRADE GLIOMA
    Chastagner, P.
    Devictor, B.
    Geoerger, B.
    Aerts, I.
    Leblond, P.
    Frappaz, D.
    Gentet, J. C.
    Pall-Kondolff, S.
    Andre, N.
    PEDIATRIC BLOOD & CANCER, 2015, 62 : S159 - S159
  • [40] BORTEZOMIB, PEGYLATED LIPOSOMAL DOXORUBICIN AND DEXAMETHASONE (B-PEGHLD-D) AS THERAPY FOR PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOIVIA
    Gozzetti, A.
    Marchini, E.
    Fabbri, A.
    Bocchia, M.
    Defina, M.
    Lauria, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 437 - 437
12345